Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease.

The prevalence of obesity and related conditions like non-alcoholic fatty liver disease (NAFLD) is increasing worldwide and therapeutic options are limited. Alternative treatment options are therefore intensively sought after. An interesting candidate is the natural polyphenol resveratrol (RSV) that activates adenosinmonophosphate-activated protein kinase (AMPK) and silent information regulation-2 homolog 1 (SIRT1). In addition, RSV has known anti-oxidant and anti-inflammatory effects. Here, we review the current evidence for RSV-mediated effects on NAFLD and address the different aspects of NAFLD and non-alcoholic steatohepatitis (NASH) pathogenesis with respect to free fatty acid (FFA) flux from adipose tissue, hepatic de novo lipogenesis, inadequate FFA β-oxidation and additional intra- and extrahepatic inflammatory and oxidant hits. We review the in vivo evidence from animal studies and clinical trials. The abundance of animal studies reports a decrease in hepatic triglyceride accumulation, liver weight and a general improvement in histological fatty liver changes, along with a reduction in circulating insulin, glucose and lipid levels. Some studies document AMPK or SIRT1 activation, and modulation of relevant markers of hepatic lipogenesis, inflammation and oxidation status. However, AMPK/SIRT1-independent actions are also likely. Clinical trials are scarce and have primarily been performed with a focus on overweight/obese participants without a focus on NAFLD/NASH and histological liver changes. Future clinical studies with appropriate design are needed to clarify the true impact of RSV treatment in NAFLD/NASH patients.

• Publication year

  2014

• Venue

  World Journal of Hepatology

• Publication date

  2014-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.4254/wjh.v6.i4.188PMID 24799987PMCID PMC4009474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease.

  2014cited by this paper
• A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations

  2013cited by this paper
• Resveratrol Suppresses PAI-1 Gene Expression in a Human In Vitro Model of Inflamed Adipose Tissue

  2013cited by this paper
• Resveratrol has inhibitory effects on the hypoxia-induced inflammation and angiogenesis in human adipose tissue in vitro.

  2013cited by this paper
• Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning.

  2013cited by this paper
• High-Dose Resveratrol Supplementation in Obese Men

  2013cited by this paper
• Emerging drugs for non-alcoholic steatohepatitis

  2013cited by this paper
• Probiotics as a Novel Treatment for Non-Alcoholic Fatty Liver Disease; A Systematic Review on the Current Evidences

  2013cited by this paper
• Melatonin attenuates high fat diet-induced fatty liver disease in rats.

  2013cited by this paper
• Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet.

  2013cited by this paper
• Negative regulation of inflammation by SIRT1.

  2013cited by this paper
• Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.

  2013cited by this paper
• The effects of chronic AMPK activation on hepatic triglyceride accumulation and glycerol 3-phosphate acyltransferase activity with high fat feeding

  2013cited by this paper
• Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010.

  2013cited by this paper
• Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats.

  2013cited by this paper
• Resveratrol Suppresses T0901317-Induced Hepatic Fat Accumulation in Mice

  2013cited by this paper
• Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

  2013cited by this paper
• Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats.

  2013cited by this paper
• Combined Influence of Insulin Resistance, Overweight/Obesity, and Fatty Liver as Risk Factors for Type 2 Diabetes

  2012cited by this paper
• "Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats".

  2012cited by this paper
• Effects of resveratrol on the amelioration of insulin resistance in KKAy mice.

  2012cited by this paper
• Endoplasmic reticulum stress in nonalcoholic fatty liver disease.

  2012cited by this paper
• Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance.

  2012cited by this paper
• SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.

  2012cited by this paper
• Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice

  2012cited by this paper
• Mitochondrial Roles and Cytoprotection in Chronic Liver Injury

  2012cited by this paper
• Dietary resveratrol increases the expression of hepatic 7α-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice

  2012cited by this paper
• Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats".

  2012cited by this paper
• Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet.

  2012cited by this paper
• Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases

  2012cited by this paper
• Resveratrol Attenuates Obesity-Associated Peripheral and Central Inflammation and Improves Memory Deficit in Mice Fed a High-Fat Diet

  2012cited by this paper
• Thiazolidinedione safety

  2012cited by this paper
• Inflammation and fibrogenesis in steatohepatitis

  2012cited by this paper
• Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

  2012cited by this paper
• Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice.

  2012cited by this paper
• Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents.

  2012cited by this paper
• Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats.

  2012cited by this paper
• Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice.

  2012cited by this paper
• Mitochondrial dysfunction in nonalcoholic steatohepatitis

  2011cited by this paper
• The role of oxidative stress in non-alcoholic steatohepatitis.

  2011cited by this paper
• Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome.

  2011cited by this paper
• High dose of dietary resveratrol enhances insulin sensitivity in healthy rats but does not lead to metabolite concentrations effective for SIRT1 expression.

  2011cited by this paper
• Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle.

  2011cited by this paper
• Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

  2011cited by this paper
• Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy.

  2011cited by this paper
• Distinct Effects of Calorie Restriction and Resveratrol on Diet-Induced Obesity and Fatty Liver Formation

  2011cited by this paper
• Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice.

  2011cited by this paper
• Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress

  2011cited by this paper
• Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling.

  2011cited by this paper
• Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT )

  2011cited by this paper
• Closer association of mitochondria with lipid droplets in hepatocytes and activation of Kupffer cells in resveratrol-treated senescence-accelerated mice

  2011cited by this paper
• Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

  2011cited by this paper
• Anti‐diabetic effects of resveratrol

  2011cited by this paper
• SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease

  2011cited by this paper
• AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.

  2011cited by this paper
• Sirtuin 1 in lipid metabolism and obesity

  2011cited by this paper
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

  2011cited by this paper
• Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

  2010cited by this paper
• SIRT1 Deacetylates and Inhibits SREBP-1C Activity in Regulation of Hepatic Lipid Metabolism*

  2010cited by this paper
• Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

  2010cited by this paper
• Impact of Sirt1 on mammalian aging

  2010cited by this paper
• Resveratrol and liver disease: from bench to bedside and community

  2010cited by this paper
• Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo

  2010cited by this paper
• Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP.

  2010cited by this paper
• Resveratrol, a red wine polyphenol, attenuates lipopolysaccharide-induced oxidative stress in rat liver.

  2010cited by this paper
• Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer.

  2010cited by this paper
• Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats.

  2010cited by this paper
• Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2

  2010cited by this paper
• Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients

  2010cited by this paper
• Resveratrol inhibits dimethylnitrosamine-induced hepatic fibrosis in rats

  2010cited by this paper
• AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability.

  2010cited by this paper
• A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

  2010cited by this paper
• Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

  2010cited by this paper
• SIRT1 Transcription Is Decreased in Visceral Adipose Tissue of Morbidly Obese Patients with Severe Hepatic Steatosis

  2010cited by this paper
• Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants

  2010cited by this paper
• Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo

  2009cited by this paper
• AMP-Activated Protein Kinase–Deficient Mice Are Resistant to the Metabolic Effects of Resveratrol

  2009cited by this paper
• AMPK: Lessons from transgenic and knockout animals.

  2009cited by this paper
• Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets.

  2009cited by this paper
• Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.

  2009cited by this paper
• Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial

  2009cited by this paper
• Inflammatory Pathways in Liver Homeostasis and Liver Injury

  2009cited by this paper
• Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats.

  2009cited by this paper
• Complications of bariatric surgery: implications for the covering physician.

  2009cited by this paper
• The challenge of developing novel pharmacological therapies for non‐alcoholic steatohepatitis

  2009cited by this paper
• Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal

  2009cited by this paper
• Resveratrol attenuates lipopolysaccharide-induced hepatitis in D-galactosamine sensitized rats: role of nitric oxide synthase 2 and heme oxygenase-1.

  2009cited by this paper
• FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states.

  2009cited by this paper
• SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase*

  2008cited by this paper
• Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats.

  2008cited by this paper
• Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase

  2008cited by this paper
• Resveratrol inhibits nonalcoholic fatty liver disease in rats

  2008cited by this paper
• Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease

  2008cited by this paper
• Resveratrol inhibits cell growth by inducing cell cycle arrest in activated hepatic stellate cells

  2008cited by this paper
• Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters.

  2008cited by this paper
• Assessment of the bone quality of black male athletes using calcaneal ultrasound: a cross-sectional study

  2008cited by this paper
• Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes

  2008cited by this paper
• Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet.

  2008cited by this paper
• Resveratrol prevents fibrosis, NF‐κB activation and TGF‐β increases induced by chronic CCl4 treatment in rats

  2008cited by this paper
• Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults

  2008cited by this paper

• Effects of Quercetin on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Flavonoids in Metabolic Disease: A Narrative Review of Mechanisms and Therapeutic Potential

  2025cites this paper
• Effect of resveratrol on key signaling pathways including SIRT1/AMPK/Smad3/TGF-β and miRNA-141 related to NAFLD in an animal model

  2025cites this paper
• Resveratrol Relieves Hepatic Steatosis and Enhances the Effects of Atorvastatin in a Mouse Model of NAFLD by Regulating the Renin‐Angiotensin System, Oxidative Stress, and Inflammation

  2025cites this paper
• Effects of polyphenol supplementation on hepatic steatosis, intima-media thickness and non-invasive vascular elastography in obese adolescents: a pilot study protocol

  2024cites this paper
• Therapeutic Potential of Resveratrol and Atorvastatin Following High-Fat Diet Uptake-Induced Nonalcoholic Fatty Liver Disease by Targeting Genes Involved in Cholesterol Metabolism and miR33

  2023cites this paper
• Effects of Resveratrol Supplementation on Nonalcoholic Fatty Liver Disease Management

  2023cites this paper
• Molecular Mechanisms of Oxidative Stress in Acute Kidney Injury: Targeting the Loci by Resveratrol

  2023cites this paper
• The Effects of Resveratrol Supplementation on the Metabolism of Lipids in Metabolic Disorders.

  2023cites this paper
• Resveratrol and Saroglitazar: A Promising Combination for Targeting TGF-β/Smad3 Signaling and Attenuating Inflammatory Response in Nonalcoholic Steatohepatitis in Rats

  2023cites this paper
• A novel combination of metformin and resveratrol alleviates hepatic steatosis by activating autophagy through the cAMP/AMPK/SIRT1 signaling pathway

  2023cites this paper
• Tamoxifen induced hepatic steatosis in high-fat feeding rats through SIRT1-Foxo1 suppression and LXR-SREBP1c activation.

  2022cites this paper
• Resveratrol therapy improves liver function via estrogen-receptors after hemorrhagic shock in rats

  2022cites this paper
• Free-radical liver damage correction in mechanical jaundice

  2022cites this paper
• Resveratrol Attenuates High-Fat Diet–Induced Hepatic Lipotoxicity by Upregulating Bmi-1 Expression

  2022cites this paper
• Nutraceuticals in hepatic diseases

  2021cites this paper
• Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus

  2021cites this paper
• Resveratrol Alleviates Acute Campylobacter jejuni Induced Enterocolitis in a Preclinical Murine Intervention Study

  2020cites this paper
• Resveratrol Metabolites Are Able to Reduce Steatosis in Cultured Hepatocytes

  2020cites this paper
• Cardiolipin deficiency elevates susceptibility to a lipotoxic hypertrophic cardiomyopathy.

  2020cites this paper
• The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease.

  2020cites this paper
• The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression

  2019cites this paper
• Influence of Resveratrol on Sphingolipid Metabolism in Hepatocellular Carcinoma Cells in Lipid Overload State.

  2019cites this paper
• Health benefits of resveratrol: Evidence from clinical studies

  2019cites this paper
• Resveratrol protects against hepatic insulin resistance in a rat's model of non‐alcoholic fatty liver disease by down‐regulation of GPAT‐1 and DGAT2 expression and inhibition of PKC membranous translocation

  2019cites this paper
• Lipid Pathway in Liver Cells and Its Modulation by Dietary Extracts

  2019cites this paper
• Resveratrol

  2018cites this paper
• Resveratrol improves high-fat diet induced fatty liver and insulin resistance by concomitantly inhibiting proteolytic cleavage of sterol regulatory element-binding proteins, free fatty acid oxidation, and intestinal triglyceride absorption.

  2018cites this paper
• Resveratrol Ameliorates Lipid Droplet Accumulation in Liver Through a SIRT1/ ATF6-Dependent Mechanism

  2018cites this paper
• Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

  2018cites this paper
• Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes

  2018cites this paper
• Involvement of 5′AMP-Activated Protein Kinase (AMPK) in the Effects of Resveratrol on Liver Steatosis

  2018cites this paper
• Comprehensive Metabolomic Analysis in Blood, Urine, Fat, and Muscle in Men with Metabolic Syndrome: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Resveratrol after Four Months’ Treatment

  2017cites this paper
• Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease

  2017cites this paper
• Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance

  2017cites this paper
• Anti-Inflammatory Diet in Clinical Practice: A Review

  2017cites this paper
• Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats

  2017cites this paper
• The red wine polyphenol, resveratrol improves hemodynamics, oxidative defence and aortal structure in essential and malignant hypertension

  2017cites this paper
• Effect of resveratrol on experimental non‐alcoholic fatty liver disease depends on severity of pathology and timing of treatment

  2016cites this paper
• Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

  2016cites this paper
• The Effects of Resveratrol Supplementation in Overweight and Obese Humans: A Systematic Review of Randomized Trials

  2016cites this paper
• Protective effects of resveratrol and its analogs on age-related macular degeneration in vitro

  2016cites this paper
• Protective effects of resveratrol and its analogs on age-related macular degeneration in vitro

  2016cites this paper
• Resveratrol attenuates the progress of liver fibrosis via the Akt/nuclear factor-κB pathways.

  2016cites this paper
• A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice

  2016cites this paper
• Resveratrol Attenuates Aβ25–35 Caused Neurotoxicity by Inducing Autophagy Through the TyrRS-PARP1-SIRT1 Signaling Pathway

  2016cites this paper
• Anti-Inflammatory and Organ-Protective Effects of Resveratrol in Trauma-Hemorrhagic Injury

  2015cites this paper
• Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action.

  2015cites this paper
• Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway.

  2015cites this paper
• The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.

  2015cites this paper
• Critical review of resveratrol in xenobiotic-induced hepatotoxicity.

  2015cites this paper
• Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats.

  2015cites this paper
• Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?

  2015cites this paper
• Effect of resveratrol on experimental non-alcoholic steatohepatitis.

  2015cites this paper
• Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

  2015cites this paper